MedPath

Bicara Therapeutics and Zenas BioPharma Aim for $200 Million IPOs

• Bicara Therapeutics plans a $200 million IPO to advance ficerafusp alfa, a bifunctional antibody targeting EGFR and TGF-β for solid tumors. • Zenas BioPharma also seeks $200 million through an IPO to support obexelimab, a CD19 and FcγRIIb targeting antibody in Phase 3 for IgG4-RD. • Both companies anticipate using the IPO proceeds to fund clinical trials and further develop their respective pipelines of novel therapeutics. • The IPOs reflect continued investor interest in innovative biotech companies developing targeted therapies for cancer and autoimmune diseases.

Two biotech companies, Bicara Therapeutics and Zenas BioPharma, are set to launch IPOs next Thursday, each aiming to raise $200 million. These offerings highlight the ongoing investor interest in novel therapeutic approaches for cancer and autoimmune diseases.

Bicara Therapeutics Focuses on Solid Tumors

Bicara Therapeutics (BCAX) intends to raise $200 million with an anticipated market cap of $865 million. Their lead candidate, ficerafusp alfa, is a bifunctional antibody designed to target both epidermal growth factor receptor (EGFR) and transforming growth factor beta (TGF-β). This dual-targeting mechanism aims to inhibit cancer cell survival and proliferation by blocking EGFR, while also suppressing the immunosuppressive TGF-β signaling within the tumor microenvironment. The company plans to initiate a pivotal Phase 2/3 trial in late 4Q24 or early 1Q25 to further evaluate ficerafusp alfa's efficacy.

Zenas BioPharma Targets Autoimmune Diseases

Zenas BioPharma (ZBIO) is also looking to secure $200 million, targeting a market cap of $685 million. Their lead candidate, obexelimab, is a bifunctional monoclonal antibody that targets CD19 and FcγRIIb. This approach aims to inhibit the activity of cells implicated in various autoimmune diseases without depleting them. Obexelimab is currently in Phase 3 clinical trials for IgG4-Related Disease (IgG4-RD) and Phase 2 trials for multiple sclerosis (MS) and systemic lupus erythematosus (SLE). Topline data for the IgG4-RD trial is expected in 2025. Zenas BioPharma's pipeline includes other clinical-stage programs targeting immunological pathways.

IPO Details

Bicara Therapeutics and Zenas BioPharma both plan to offer 11,765,000 and 11,760,000 shares respectively, priced between $16 and $18. Morgan Stanley and TD Cowen are acting as bookrunners for Bicara Therapeutics, while Morgan Stanley and Jefferies are managing the Zenas BioPharma IPO.
These IPOs represent a significant step for both companies as they seek to advance their clinical programs and address unmet needs in oncology and immunology.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

J&J Submits TAR-200 for FDA Review; Lykos Therapeutics Board Shakeup

Johnson & Johnson has initiated the submission of TAR-200, a drug-device combination for bladder cancer, to the FDA under a real-time review program. Meanwhile, Lykos Therapeutics announced significant changes to its board of directors following setbacks in its MDMA therapy for PTSD.

Molecular Partners and Orano Med Expand Partnership for Cancer Therapy Development

Molecular Partners and Orano Med have announced an expanded partnership to develop Targeted Alpha Radio-Therapies for cancer, aiming to enter a first-in-human study for Radio-DARPin MP0712 against DLL3 by 2025 and co-develop a program targeting Mesothelin.

Ouro Medicines Launches with $120 Million to Develop Immune Reset Therapeutics

Ouro Medicines launched with $120 million in funding to develop antibody drugs, specifically T cell engagers, for chronic inflammatory conditions and autoimmune diseases.
The company's lead candidate, OM336, licensed from Keymed Biosciences, targets BCMA and is slated to begin Phase 1 trials in multiple autoimmune conditions in 2025.

Metsera Aims for $289 Million IPO to Advance GLP-1RA Obesity Treatment

Metsera is seeking a $289 million IPO to fund the Phase III trial of its lead candidate, MET-097i, an injectable GLP-1 receptor agonist for obesity.
MET-097i demonstrated up to 20% weight loss in Phase II trials, showcasing a long half-life that could allow for less frequent injections.

Tenvie Therapeutics Launches with $200M for Neurodegeneration Drug R&D; Sana Biotechnology Achieves Landmark in Type 1 Diabetes Transplant

Tenvie Therapeutics, backed by Arch Venture Partners and others, debuts with $200 million to develop drugs targeting neurodegenerative diseases.
Sana Biotechnology's technology enables successful pancreatic islet cell transplant in a Type 1 diabetes patient without immunosuppression.

Metsera's GLP-1 Therapy Shows Promise in Phase II Trial Amidst M&A Speculation

Metsera reported promising Phase II data for its investigational subcutaneous GLP-1 therapy, positioning it as a potential acquisition target.
The GLP-1 space is expanding into new indications like heart disease, sleep apnea, and metabolic dysfunction-associated steatohepatitis (MASH).

Maze Therapeutics Initiates Phase 2 Trial of MZE829 for APOL1 Kidney Disease

Maze Therapeutics has dosed the first patient in its Phase 2 HORIZON study, evaluating MZE829 for APOL1 kidney disease (AKD).
The HORIZON trial is an open-label, basket design study including AKD patients with varying degrees of proteinuria and diabetic AKD.

FDA Approves Ziihera (zanidatamab-hrii) for HER2-Positive Biliary Tract Cancer

The FDA granted accelerated approval to Ziihera (zanidatamab-hrii) for previously treated, unresectable or metastatic HER2-positive biliary tract cancer (BTC).
Approval was based on a 52% objective response rate and a 14.9-month median duration of response in the HERIZON-BTC-01 clinical trial.

Merck & Co. Acquires Curon Bio's Bispecific T-Cell Engager for $1.3 Billion

Merck & Co. has acquired Curon Biopharmaceutical's CN201, a CD3xCD19 bispecific T-cell engager, for up to $1.3 billion, strengthening its oncology pipeline.
CN201 is currently in Phase 1 and Phase 1b/2 trials for relapsed or refractory non-Hodgkin’s lymphoma and acute lymphocytic leukemia, showing encouraging early data.

Bicara, Zenas, and MBX Bio Launch IPOs, Raising $703M for Clinical Trials

Bicara Therapeutics raised $315 million to fund a pivotal trial of ficerafusp alfa for head and neck squamous cell carcinoma (HNSCC).
Zenas Biopharma secured $225 million to advance obexelimab, a bifunctional antibody, through Phase 3 trials for IgG4-related disease and Phase 2 trials for multiple sclerosis, lupus, and wAIHA.

Reference News

[1]
US IPO Week Ahead: A pair of biotechs plan to complete $200 million deals
renaissancecapital.com · Sep 7, 2024

Two biotechs, Bicara Therapeutics and Zenas BioPharma, plan to raise $200 million each in IPOs. Bicara's ficerafusp alfa...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy